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3 groups based on receipt of cardiac catheterization (cath) < 12 hours of lytics (early 
cath,N=261), > 12h after lytics (late cath,N=451) or no cath (conservative treat- 
ment,N=1056). The likelihood of in-hospital mortality and reinfarction was determined 
using multivariate analysis. 
Results: 41% pts underwent cath during index hospitalization. 89% of eady cath pts had 
a PCI (pemutaneous coronary intervention) as opposed to 61% of the late cath group (p 
< 0.0001). The outcomes of the early cath group did not differ significantly from the lyrics 
only group. However, the incidence of in-hospital death was significantly lower in the late 
cath group as compared to the lytics only group (2% Versus 6.8%, p 0.0002). This 
remained true even after controlling for differences in baseline and in-hospital character° 
istics between the 2 groups (late oath mortality OR 0.3, 95%CI 0.13-0.63). The likelihood 
of a reinfarction was, however, significantly high in the late cath group. 
Conclusions: Although lytics substantially reduce mortality after an acute STE MI many 
pts may derive an additional benefit from the use of a cardiac cath and, if indicated, a 
PCI, especially if performed non-urgently. 
Odds of death and reinfarction during Index hospitalization 
(* compared with lytlcs only group) 
DEATH DEATH REINFARCTION REINFARCTION 
OR 95%CI OR 95%CI 
Late Cath 0.3 0.13-0.63 3.1 1.78-5.23 
Cath 0.5 0.27-0.79 2.5 1.49-4.25 
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822-1 Elevated White Blood Cell Count Is Associated With 
Higher Mortality in Patients With Acute Coronary 
Syndromes Independent of Other Cardiac Markers: A 
TACTICS - TIM118 Substudy 
Marc S. Sabatine. David A. Morrow, Sabina A. Murphy, Laura A. Demopoulos, Peter M. 
DiBattista, Carolyn H. McCabe, Christopher P. Cannon, Eugene Breunwald, Michael 
Gibson, Brigham and Women's Hospital, Boston, Massachusetts. 
Background & Methods: Higher white blood cell counts (WBCC) have been associated 
with higher mortality in the setting of acute coronary syndromes (ACS). We sought to 
examine if this relationship was true independent of other cardiac markers of inflamma- 
tion and/or infarction in TACTICS - TIM118. 
Results: The median WBCC (103/ram 3) at baseline was 8.1 [interquartile range (IR) 6.7- 
10.1]. Median WBCC was higher in patients who died by 30 days (9.1, IR 7.8-12 vs. 8.1, 
IR 6.6-10.1; p=0.0016) and 180 days (8.75, IR 7.6-10.95 vs. 8.1, IR 6.6-10.1; p=0.0047). 
Of the 1841 patients with WBCC & C-reactive protein (CRP) data, patients with a low 
WBCC (<25 th percentile) and a low CRP (<1.5 mg/dL) had a 6-month mortality rate of 
0,7%, those with a low CRP but a high WBCC had a rate of 2.8%, and those with a high 
CRP regardless of WBCC had a mortality rate of 6.2% (p<0.0001, Z 2 for trend). In a Cox 
proportional hazards model adjusted for age, smoking, craatinine, prior MI, prior aspirin 
use, troponin level, and ST deviation, patients with low CRP but high WBCC remained at 
significantly higher risk of death at 180 days [hazard ratio (HR) 5.4, p=0.02], and patients 
with high CRP were at even higher risk (HR 12.2, p=0.0007). 
Conclusion: Higher baseline WBCC are associated with a higher risk of 6-month mortal- 
ity. Even after adjusting for traditional risk factors, including troponin and ST deviation, 
assessment of two inflammatory markers, WBCC and CRP, can be used to stratify 
patients with ACS into low, intermediate, and high 6-month mortality risk. 
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822-2 Elevated C Reactive Protein (CRP) Is Associated With a 
Higher Risk of Thrombotic Occlusion and Poorer Flow 
Following Percutaneous Coronary Intervention in 
Patients With Acute Coronary Syndromes: A TACTICS 
TIM118 Angiographic Substudy 
Michael Gibson, David Morrow, Ralph Vicari, Graham Wong, Laura Demopoious, Peter 
DiBattista, Sabina A. Murphy, Chdstopher P. Cannon, Eugene Braunwald, Harvard 
Clinical Research Institute, Boston, Massachusetts, Brigham and Women's Hospital 
Boston, Massachusetts. 
Background & Methods: Higher CRP levels are associated with a higher risk of cardiac 
events. The relationship between baseline CRP and angiogrephic findings has not been 
explored. In the TACTICS / TIMI 18 trial of invasive versus conservative strategies in the 
management of ACS, we hypothesized that elevations in CRP would be associated with 
unfavorable angiogrephic findings such as a higher risk of thrombotic occlusion. Results: 
Patients with a closed artery (TIMI Flow Grade (TFG) 0/1) had higher CRPs than patients 
with an open artery (TFG 2/3) (1.98 _+ 2.7 mg/dL, n=63 vs 1.22 + 1.8 mg/dL, n=392, 
p=0.005), and conversely a CRP > 2X the threshold (> 3.0 mg/dL) was associated with a 
higher risk of thrombotic occlusion (26.8%, 15/56 vs 12.0%, 48/399 p=0.003). Likewise, 
an elevated CRP > 2X threshold was associated with higher (i.e, slower) Corrected TIMI 
Frame Counts (CTFCs) on diagnostic catheterization (58.2 + 36.6, median 45.3, n=41, 
vs 43.1 + 30.6, median 32, n= 341, p=0.037 comparing medians). Even among patients 
who were troponin negative, those pts with a closed artery had a higher CRP compared 
to those with an open artery (1.84 _+ 2.4, n=10 vs 0.78 + 1.5, n=156, p=0.04) and again a 
CRP > 2X the threshold was associated with a higher risk of thrombotic occlusion 
(30.0%, 3/10 vs 4.5%, 7/156 p=0.001 ). Pts. who did not achieve TFG 3 following percuta- 
neous coronary intervention (PCI) had higher CRP levels (2.25 .t: 3.5 mg/dL, n=19 vs 
1.31 _+ 1.9 mg/dL, n=356, p=O.05), and likewise a CRP > 2X threshold tended to be asso- 
ciated with a lower incidence of TFG 3 after PCl (89.6%, 43/48, vs95.7%, 313/327, 
p=O.07). Those pts with no reflow or distal embolization during PCI had higher CRP lev- 
els (2.81 + 3.5, n=9 vs 1.33 + 2.0, n=367, p=0.034). There was no association between 
CRP and either disease extent (1,2,3 vessel disease) or tissue level perfusion as 
assessed using the TIMI Myocardial Perfusion Grade. Conclusions: Higher baseline 
CRP values are associated with a higher risk of thrombotic vessel occlusion on diagnos- 
tic cardiac catheterization and a lower incidence of TIMI 3 Flow after PCI. 
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822-3 Ef fect  o f  A torvasts t in  on C-React ive Prote in in Patients 
With Acute Coronary Syndromes: A Substudy of the 
MIRACL Trial 
Scott Kinlav. Neder Rifai, Peter Libby, Peter Ganz on behalf of the MIRACL Investigators, 
Brigham and Women's Hospital Boston, Massachusetts, Children's Hospital Boston, 
Boston, Massachusetts. 
Background: Coronary lesions of patients with acute coronary syndromes are charac- 
terized by intense inflammation. The MIRACL trial showed that atorvastatin 80 mg/day 
reduced recurrent ischemic events in the first 16 weeks. The purpose of this study was to 
determine whether intensive lipid lowering can reduce serum C-reactive protein (CRP), a 
marker of inflammation, in patients with unstable angina or non-Q-wave MI. Methods: 
Blood samples were collected at baseline and at 16 weeks from 2,322 of 3,086 patients 
participating in the MIRACL trial. C-reactive protein (CRP) was measured by a highly 
sensitive immunoassay. The change in CRP was compared between patients randomly 
assigned to atorvastatin vs. placebo. The change in CRP was also evaluated separately 
in patients with unstable angina and non-Q-wave myocardial infarction. Results: The 
baseline median CRP was similar in the patients assigned to atorvastatin (10.0 mg/L) 
and placebo (9.9 mg/L), (p=NS). The reduction in CRP over 16 weeks of treatment was 
significantly greater in patients on atorvastatin (-7.5 mg/L) compared to placebo (-6.0 mg/ 
L, p<0.001). Atorvastatin led to a greater reduction in CRP in patients with non-Q-wave 
MI (-15.9 vs -10.0 mg/L, atorvastatin vs. placebo, p=0.011), as well as in patients with the 
unstable angina (-3.5 vs -2.5 rag/L, atorvastatin vs. placebo, p=0.003). Conclusion: 
Atorvastatin (80mg/day) reduced CRP, a marker of inflammation, in patients with acute 
coronary syndromes. This was observed in patients with non-Q-wave MI as well as 
unstable angina. Thus, in patients with acute coronary syndromes, atorvastatin reduces 
inflammation, a mechanism associated with plaque stabilization. This effect may contrib- 
ute to the clinical benefit observed in the MIRACL trial. 
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822-4 Detection of Cardiac Neurohormonal Activation 
Complements Cardiac Troponin for Predicting 
Recurrent Events in UA/NSTEMh Prognostic Utility of 
BNP in TACTICS-TIM118 
David A. Morrow. James A. de Lemos, Marc S. Sabatine, Sabine A. Murphy, Peter M. 
DiBattiste, Carolyn H. McCabe, Christopher P. Cannon, Eugene Braunwald, Brigham & 
Women's Hospital Boston, Massachusetts. 
B-type natriuretic peptide (BNP) is released in response to increased ventdcular wall 
stress. Recent findings indicate that plasma levels of BNP predict mortality among 
patients (pts) with unstable angina & non-ST elevation MI. However, data in this popula- 
tion, and in combination with cardiac troponins are few. METHODS: Baseline levels of 
BNP (Biosite Diagnostics) and cTnl (Bayer Diagnostics) were available for 1541 pts with 
non-ST elevation ACS randomized to early invasive(INV) vs. conservative(CONS) man- 
